Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 34Carboplatin 32pembrolizumab 28Pemetrexed 27Magnetic Resonance Spectroscopy 27Cisplatin 22Paclitaxel 15Gemcitabine 13durvalumab 12Docetaxel 12osimertinib 11Nivolumab 11atezolizumab 8Immunoglobulin G 8Disulfides 8Taxes 7Etoposide 7130-nm albumin-bound paclitaxel 7Radiotherapy 6Radiosurgery 6Radiation 6Platinum 6Cetuximab 6Biopsy 6X-Rays 51,2-diaminocyclohexaneplatinum II citrate 5Ramucirumab 4Observation 4Irinotecan 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Tyrosine Kinase Inhibitors × 30 days × Clear all
NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡